Article
Personalized medicine for glioblastoma: current challenges and future opportunities.
Current molecular medicine - 1 Mar 2013
Zhu J-J, Wong E T
Abstract excerpt
The failure to control glioblastoma progression is a major challenge for neuro-oncologists. Emerging data indicate that genetic and epigenetic heterogeneities within tumor cells play a dominant role in the development of resistant disease. These heterogeneities develop because driver mutations enable the proliferation of certain clones of transformed cells within the tumor microenvironment while pre-existing...
Topics
- Cell Cycle
- Cell Proliferation
- ErbB Receptors
- Erlotinib Hydrochloride
- Genetic Variation
- Glioblastoma
- Humans
- Isocitrate Dehydrogenase
- MicroRNAs
- Precision Medicine
- Protein Kinase Inhibitors